Certified by Founder
Lodge
Evommune
start up
United States
- Palo Alto, California
- 27/04/2023
- Series B
- $50,000,000
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.
Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.
Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
- Industry Biotechnology Research
- Website https://www.evommune.com/
- LinkedIn https://www.linkedin.com/company/evommune/
WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Redwood Materials | $425,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)